guidance

Boston Scientific’s selloff is what a real medtech reset looks like

Boston Scientific’s plunge looks like a real reset, not a bargain-bin overreaction. Management already cut 2026 growth guidance, then reinforced that Watchman weakness is tied to a worsening procedure mix that the market can’t just wave away.